Montelukast Aurovitas

Montelukast, the active ingredient in Montelukast Aurovitas, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients requiring leukotriene pathway modulation.

GNH USA supplies Montelukast Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is used to manage respiratory conditions mediated by leukotrienes.

Asthma: improves control of chronic asthma and reduces frequency of exacerbations. Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal allergies. Exercise‑induced bronchoconstriction: prevents narrowing of airways during or after physical activity.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema, or anaphylaxis - Neuropsychiatric events including agitation, depression, or suicidal thoughts - Elevated liver enzymes or hepatitis - Eosinophilic granulomatosis with polyangiitis - Severe skin reactions such as Stevens‑Johnson syndrome - Anaphylactic shock

Before prescribing Montelukast, clinicians should consider several safety aspects.

Assess patient history: evaluate for prior hypersensitivity to montelukast or similar agents. Monitor for neuropsychiatric symptoms: watch for mood changes, depression, or suicidal thoughts. Consider liver function: check baseline hepatic enzymes in patients with liver disease. Use caution in elderly: adjust monitoring as needed. Avoid use in patients with known hypersensitivity to the drug. Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Montelukast can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital, rifampin, carbamazepine: may significantly reduce montelukast plasma concentrations. - Strong CYP3A4 inhibitors (ketoconazole, itraconazole): may increase exposure, raising risk of adverse effects. - Live vaccines: theoretical risk of altered immune response.

Moderate Interactions (Monitor Closely): - Other leukotriene modifiers: additive effects on leukotriene pathways. - Warfarin: possible alteration of anticoagulant effect. - Beta‑agonists: no direct interaction but monitor overall asthma control.